FIELD: biotechnology.
SUBSTANCE: disclosed are isolated antibodies and antigen-binding fragments thereof, specifically binding programmed cell death protein ligand 1 (PD-L1), coding nucleic acids thereof, as well as vectors and host cells for producing said antibodies. Also disclosed is a pharmaceutical composition, an immunoconjugate and a fusion protein comprising the disclosed antibodies. Invention also relates to methods of treating PD-1 mediated diseases.
EFFECT: antibodies to PD-L1 have high affinity to PD-L1, perform the function of PD-L1 inhibition, have less immunogenicity compared to their unmodified parental antibodies in this biological species, are able to increase T-cell proliferation and IL-2 secretion in a mixed lymphocytic reaction.
22 cl, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTI-PD-1 ANTIBODY | 2015 |
|
RU2722212C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
